In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae
- PMID: 11796366
- PMCID: PMC127069
- DOI: 10.1128/AAC.46.2.517-518.2002
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae
Abstract
The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
Similar articles
-
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.Int J Antimicrob Agents. 2003 Jun;21(6):578-80. doi: 10.1016/s0924-8579(03)00061-x. Int J Antimicrob Agents. 2003. PMID: 12791473
-
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.Antimicrob Agents Chemother. 2014;58(3):1800-1. doi: 10.1128/AAC.02263-13. Epub 2013 Dec 23. Antimicrob Agents Chemother. 2014. PMID: 24366753 Free PMC article.
-
Comparative in vitro activity of garenoxacin against Chlamydia spp.J Antimicrob Chemother. 2002 Sep;50(3):407-10. doi: 10.1093/jac/dkf145. J Antimicrob Chemother. 2002. PMID: 12205067
-
Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.J Antimicrob Chemother. 2000 Apr;45 Suppl 1:35-9. doi: 10.1093/jac/45.suppl_3.35. J Antimicrob Chemother. 2000. PMID: 10824030 Review.
-
Activity of quinolones against Chlamydia pneumoniae.Drugs. 1999;58 Suppl 2:78-81. doi: 10.2165/00003495-199958002-00015. Drugs. 1999. PMID: 10553711 Review.
Cited by
-
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.Antimicrob Agents Chemother. 2003 Jul;47(7):2327-9. doi: 10.1128/AAC.47.7.2327-2329.2003. Antimicrob Agents Chemother. 2003. PMID: 12821490 Free PMC article.
-
Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.Antimicrob Agents Chemother. 2005 Jan;49(1):406-7. doi: 10.1128/AAC.49.1.406-407.2005. Antimicrob Agents Chemother. 2005. PMID: 15616321 Free PMC article.
-
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003. Antimicrob Agents Chemother. 2003. PMID: 12499185 Free PMC article.
-
In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.Antimicrob Agents Chemother. 2003 Apr;47(4):1447-8. doi: 10.1128/AAC.47.4.1447-1448.2003. Antimicrob Agents Chemother. 2003. PMID: 12654690 Free PMC article.
-
Mycoplasma genitalium: should we treat and how?Clin Infect Dis. 2011 Dec;53 Suppl 3(Suppl 3):S129-42. doi: 10.1093/cid/cir702. Clin Infect Dis. 2011. PMID: 22080266 Free PMC article.
References
-
- Barry, A. I., and P. C. Fuchs. 1997. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J. Chemother. 9:9-16. - PubMed
-
- Centers for Disease Control and Prevention. 1998. 1998 Guidelines for the treatment of sexually transmitted diseases. Morb. Mortal. Wkly. Rep. 47(RR-1):53-60. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases